These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 15224197)

  • 1. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
    Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
    Fujitani K; Tsujinaka T; Hirao M
    Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
    Yano T; Yamazaki K; Maruyama R; Tokunaga S; Shoji F; Higashi H; Takeo S; Ichinose Y; Maehara Y;
    Lung Cancer; 2010 Feb; 67(2):184-7. PubMed ID: 19409643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
    Arai K; Iwasaki Y; Kimura Y; Takahashi K; Yamaguchi T; Honma S; Takahashi T
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1297-301. PubMed ID: 14518409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W; Kurihara M; Nakano S; Hasegawa K
    Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
    Shigekawa T; Osaki A; Sekine H; Sato N; Kanbayashi C; Sano H; Takeuchi H; Ueda S; Nakamiya N; Sugitani I; Sugiyama M; Shimada H; Hirokawa E; Takahashi T; Saeki T
    BMC Cancer; 2015 Apr; 15():253. PubMed ID: 25884795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
    Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
    Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
    Duh D; Warnez M
    J Pharm Belg; 2013 Dec; (4):35-6. PubMed ID: 24449972
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1].
    Nakano K; Koizumi H; Okugawa K; Nakamura K; Osaka Y; Tsuchiya K; Sako H; Tanabe S; Nakane Y
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):329-33. PubMed ID: 15791815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
    Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
    Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
    Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
    Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of CA19-9 producing gastric cancer treated by low-dose administration of TS-1 for adjuvant chemotherapy].
    Takashima I; Seto Y; Nagamine I; Kegoya Y; Kodoi A; Nakayama H
    Gan To Kagaku Ryoho; 2005 Apr; 32(4):503-5. PubMed ID: 15853217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.